Automating Rheumatology MCG Criteria Prior Authorizations

Navigating the complexities of rheumatology MCG criteria for prior authorizations demands precision and efficiency. Klivira streamlines the workflow, ensuring adherence to evidence-based guidelines for critical biologic and advanced therapy approvals.

Rheumatology practices face a significant prior authorization burden, driven by the high cost and strict medical necessity criteria for biologics and advanced therapies. Adhering to MCG criteria is paramount for securing approvals, yet manual processes are time-consuming and prone to errors. This directly impacts patient access to essential treatments for chronic conditions like RA, PsA, and AS.

Understanding MCG Criteria in Rheumatology

MCG Health provides evidence-based care guidelines widely adopted by payers to determine medical necessity for high-cost treatments. In rheumatology, these MCG criteria are frequently applied to biologic and targeted synthetic DMARDs, infusion therapies, and advanced imaging for conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Key Rheumatology PA Triggers Subject to MCG Criteria

Biologics, including TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab) and non-TNF biologics (e.g., tocilizumab, secukinumab).
Targeted synthetic DMARDs, such as JAK inhibitors (e.g., tofacitinib, upadacitinib).
Infusion therapies for autoimmune conditions.
Specialty drugs for specific indications like anifrolumab for SLE.
Advanced imaging (e.g., MRI for inflammatory arthritis) and DEXA scans for osteoporosis.

Navigating Documentation Requirements for MCG Adherence

Adhering to MCG criteria for rheumatology often requires comprehensive documentation that aligns with ACR Treatment Guidelines. This includes precise ICD-10 diagnosis codes with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA), objective disease activity scores like DAS28 or PASI, and evidence of prior conventional DMARD trials or step therapy compliance.

Common Denial Reasons Related to MCG Criteria in Rheumatology

Failure to document completion of required step therapy, including specific prior agent trials or biosimilar substitution mandates.
Insufficient or missing disease activity scores (e.g., DAS28, CDAI) or other objective measures.
Lack of documentation for pre-initiation screenings, such as TB or hepatitis B/C.
Inadequate trial duration of conventional DMARDs as specified by payer policy.
Request for off-indication use of biologics without explicit payer policy support.

Klivira's Solution for Rheumatology MCG Criteria Automation

Klivira's prior authorization automation platform is engineered to address the specific demands of rheumatology MCG criteria. Our system incorporates ACR-guideline-aware policy logic for step therapy sequencing and manages the complexities of biosimilar substitution mandates. By automating data extraction from EMRs and connecting directly to payer portals, Klivira ensures that all required documentation is submitted accurately and promptly, reducing manual effort and accelerating approvals.

EMR and Payer Integration for Seamless Workflow

Klivira integrates directly with leading EMR systems via SMART on FHIR, extracting necessary clinical data for MCG criteria adherence. This seamless data flow supports automatic population of X12 278 transactions and ePA submissions to payer portals. For pharmacy benefit drugs, NCPDP SCRIPT standards are utilized, ensuring comprehensive coverage across both medical and pharmacy benefits commonly encountered with rheumatology biologics.

Frequently asked questions

How does Klivira handle step therapy requirements for biologics in rheumatology?

Klivira's platform incorporates ACR-guideline-aware policy logic to manage step therapy sequences for biologics and targeted DMARDs. It intelligently routes requests based on payer-specific mandates, including requirements for conventional DMARD trials and biosimilar substitution, ensuring compliance with MCG criteria.

Can Klivira manage ongoing re-authorizations for chronic rheumatology treatments?

Yes, Klivira supports the periodic re-authorization workflows typical for chronic rheumatology treatments like biologics. The system tracks approval expiry dates and prompts for necessary continuous response documentation, streamlining the re-authorization process to maintain patient access to care.

How does Klivira handle the distinction between medical and pharmacy benefit for rheumatology drugs?

Klivira's platform is designed to manage the dual benefit nature of many rheumatology biologics. It intelligently routes prior authorization requests based on whether a drug falls under the medical or pharmacy benefit, adapting to different administration modes and payer policies to ensure the correct submission channel is used.

What EMR systems does Klivira integrate with for rheumatology prior authorization?

Klivira integrates with major EMR systems using standards like SMART on FHIR. This allows for automated extraction of critical clinical data, such as diagnosis codes, disease activity scores, and screening results, directly from the patient chart to populate prior authorization requests, ensuring data accuracy and efficiency.

How does Klivira address payer-specific variations in MCG criteria for rheumatology?

Klivira's payer-policy logic is continuously updated to reflect specific variations in MCG criteria, including non-uniform policies on biosimilar substitution and step therapy. This ensures that each prior authorization request is tailored to the individual payer's requirements, minimizing denials due to policy discrepancies.